Merck Revenue Growth: 1.65%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
None selected
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
MRK Revenue Growth Rankings
| Overall | 34th percentile | 2908 of 4424 |
| Sector | 32nd percentile | 313 of 464 in Healthcare |
| Industry | 30th percentile | 14 of 20 in Drug Manufacturers - Major |
MRK Revenue Growth Range, Past 5 Years
| Minimum | -56.87% | Jun 2003 |
| Maximum | 49.05% | Sep 1994 |
| Average |
About Revenue Growth
Revenue growth illustrates sales increases/decreases over time. It is used to measure how fast a business is expanding. More valuable than a snapshot of revenue, revenue growth helps investors identify trends in order to gauge revenue growth over time.
If a company generated $75 billion in revenue during 2008 and $100 billion in revenue during 2009, the company experienced roughly a ($100 billion/$75 billion)-1 = %33 increase in revenue.
Learn More
You may also be interested in these MRK related companies
MRK News
News related to $MRK: 'FDA outlines path for lower-priced biotech drugs' http://stks.co/2L1j
about 3 days ago by TradeBot
about 3 days ago by TradeBot
$DD $MRK $MMM $HD DOW component are on the upward trends. http://stks.co/2KSG
about 3 days ago by stocktrendcharts
about 3 days ago by stocktrendcharts
Canaccord Genuity Reiterates a 'Buy' on OraSure Technologies (OSUR); Catalysts on the Horizon
Feb 09, 11:14AM Street Insider
Feb 09, 11:14AM Street Insider
$MRK Insider Sale: $1.6M of stock sold by Willie Deese (Exe V-p & Pres. Mmd) on February 8, 2012 http://stks.co/2KMv
about 3 days ago by MarketBrief
about 3 days ago by MarketBrief
YCHARTS DIVIDEND DAILY: Some “Non-Royalty” Dividends Beat the Aristocrats http://stks.co/2J5E $GE $ITW $ABT $MRK $CVX $XOM
about 4 days ago by ycharts
about 4 days ago by ycharts
$mrk Merck KGaA signs $550 mil deal with $THLD... Merck is also in a strategic collaboration w $ONTY..an @EXPstocktrader pick from $6.20 $$
about 8 days ago by EXPstocktrader
about 8 days ago by EXPstocktrader
$ONTY may need money upon FDA approval so they r not at the mercy of $MRK funding them. $OCZ did the same two days ago n it popped. Hold
about 8 days ago by EXPstocktrader
about 8 days ago by EXPstocktrader
RT @CorrelationPro Is the Rally Toast? What bulls need to watch http://stks.co/2E2F $FB $GMCR $DELL $DOW $MRK $PG $OIL $QCOM $BX $LTD $AAPL
about 10 days ago by MarketForesight
about 10 days ago by MarketForesight
R&D in Quebec pharma industry continues to erode $AZN $JNJ $SNY $MRK
about 10 days ago by michaelbabad
about 10 days ago by michaelbabad
$ARIA new high w good early volume-- Bond bt $ARIA and $MRK continues to grow with ribaforilimus panel----- NICE
about 10 days ago by zimmy818
about 10 days ago by zimmy818
@brandongreen $MRK is showing it coz of its earnings, not Astra's job cut
about 10 days ago by TradeVestor
about 10 days ago by TradeVestor
Listen to $MRK Q4 2011 earnings call (EPS 0.97 vs est 0.95) - live at 08:00 AM, ondemand after - http://stks.co/2Ctq
about 10 days ago by earningscast
about 10 days ago by earningscast
Merck $MRK reported Q4 EPS of $0.97, $0.02 better. Revenue $12.29 billion versus the consensus estimate of $12.53 billion.
about 10 days ago by Street_Insider
about 10 days ago by Street_Insider
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| MRK | 37.91 | -0.24 | -0.63% | 115.55B |
| DELL | 17.75 | -0.31 | -1.72% | 32.38B |
| WYN | 44.15 | -0.12 | -0.27% | 6.80B |
| GRRF | 2.95 | 0.00 | 0.00% | 67.05M |
| FRP | 4.42 | -0.43 | -8.87% | |
| HBAN | 5.91 | -0.12 | -2.07% | 5.10B |
| XOM | 83.80 | -1.08 | -1.27% | 401.67B |
| SHW | 98.37 | -1.13 | -1.14% | 10.21B |
| TGT | 52.43 | -0.27 | -0.51% | 35.40B |
| JNJ | 64.60 | -0.29 | -0.45% | 176.41B |
